ARCH — Arch Biopartners Share Price
Last trade - 00:00- CA$57.06m
- CA$59.79m
- CA$0.28m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Sep | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 3.89 | 0.96 | 1.98 | 2.12 | 0.28 | n/a | n/a | 32.37% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.
Directors
- Richard Muruve PRE
- Daniel Muruve CSO
- Andrew Bishop DRC
- Claude Allary IND
- Adrian Haigh IND (61)
- Richard Rossman IND
- Last Annual
- September 30th, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- November 13th, 2003
- Public Since
- October 9th, 1996
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 67,933,289
- Address
- 545 King St W., TORONTO, M5X 1A1
- Web
- https://archbiopartners.com/
- Phone
- +1 6474287031
- Contact
- Richard Muruve
- Auditors
- Baker Tilly HMA LLP
Latest News for ARCH
Upcoming Events for ARCH
Q4 2026 Arch Biopartners Inc Earnings Release
Q1 2027 Arch Biopartners Inc Earnings Release
Similar to ARCH
Aequus Pharmaceuticals
TSX Venture Exchange
Biosyent
TSX Venture Exchange
Delivra Health Brands
TSX Venture Exchange
Eastwood Bio-Medical Canada
TSX Venture Exchange
Genix Pharmaceuticals
TSX Venture Exchange
FAQ
As of Today at 01:19 UTC, shares in Arch Biopartners are trading at CA$0.84. This share price information is delayed by 15 minutes.
Shares in Arch Biopartners last closed at CA$0.84 and the price had moved by -13.4% over the past 365 days. In terms of relative price strength the Arch Biopartners share price has underperformed the Toronto Stock Exchange 300 Composite Index by -27.01% over the past year.
The overall consensus recommendation for Arch Biopartners is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreArch Biopartners does not currently pay a dividend.
Arch Biopartners does not currently pay a dividend.
Arch Biopartners does not currently pay a dividend.
To buy shares in Arch Biopartners you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.84, shares in Arch Biopartners had a market capitalisation of CA$57.06m.
Here are the trading details for Arch Biopartners:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: ARCH
Based on an overall assessment of its quality, value and momentum Arch Biopartners is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Arch Biopartners is CA$3.50. That is 316.67% above the last closing price of CA$0.84.
Analysts covering Arch Biopartners currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.16 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arch Biopartners. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +73.63%.
As of the last closing price of CA$0.84, shares in Arch Biopartners were trading +3.95% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Arch Biopartners PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Arch Biopartners' management team is headed by:
- Richard Muruve - PRE
- Daniel Muruve - CSO
- Andrew Bishop - DRC
- Claude Allary - IND
- Adrian Haigh - IND
- Richard Rossman - IND